Enjoy complimentary customisation on priority with our Enterprise License!
The antinuclear antibody test market share is expected to increase to USD 447.71 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.93%.
This antinuclear antibody test market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. The antinuclear antibody test market report also offers information on several market vendors, including Abbott Laboratories, Abcam Plc, Antibodies Inc., Bio Rad Laboratories Inc., BioVision Inc., Grifols SA, Immuno Concepts Ltd., Merck KGaA, Orgentec Diagnostika GmbH, PerkinElmer Inc., Quidel Corp., Seramun Diagnostica GmbH, Thermo Fisher Scientific Inc., Transasia Bio Medicals Ltd., Trinity Biotech Plc, Werfenlife SA, and ZEUS Scientific Inc. among others. Furthermore, this report extensively covers antinuclear antibody test market segmentation by end-user (hospitals and clinical diagnostic laboratories) and geography (North America, Europe, Asia, and Rest of World (ROW)).
Download the Free Report Sample to Unlock the Antinuclear Antibody Test Market Size for the Forecast Period and Other Important Statistics
For more insights on the market share of various regions Request for a FREE sample now!
38% of the market's growth will originate from North America during the forecast period. The US is the key market for antinuclear antibody tests in North America. However, market growth in this region will be slower than the growth of the market in other regions.
The significant increase in the R and D investment of pharmaceutical and biotechnology amid the COVID-19 pandemic in countries such as the US will facilitate the antinuclear antibody test market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The outbreak of the COVID-19 pandemic in 2020 has increased the demand for laboratory testing for COVID-19 across the world. An increase in demand for laboratory testing for infectious diseases, such as COVID-19 and chronic diseases, will be a driver for the life sciences tools and services industry in the future. The growth of the tools and services industry will continue to be strong in emerging markets such as China and India. Developed economies such as Japan and the EU will exhibit moderate growth rates.
To gain further insights on the market contribution of various segments Request for a FREE sample
The antinuclear antibody test market share growth by the hospitals segment will be significant during the forecast period. The significant increase in the number of hospitals will drive the growth of the market segment further during the forecast period. This is because hospitals are specialized healthcare institutions that offer best-in-class diagnosis and treatment services to patients with acute and complex conditions, including autoimmune disease.
This report provides an accurate prediction of the contribution of all the segments to the growth of the antinuclear antibody test market size and actionable market insights on post COVID-19 impact on each segment.
The increasing demand for ana tests is notably driving the antinuclear antibody test market growth, although factors such as stringent regulations for the approval of medical diagnostics may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the antinuclear antibody test industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Antinuclear Antibody Test Market Driver
One of the key factors driving the global antinuclear antibody test market growth is the increasing demand for ANA tests. The antibodies produced by the immune system bind to the body's own tissues. The screening test detects if such antibodies are present in the body. The demand for antinuclear antibodies tests is increasing to identify autoimmune disorders such as rheumatoid arthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, and many more. According to the Foundation for Peripheral Neuropathy report, in 2019, Guillain-Barre Syndrome (GBS) affects about 3,000-6,000 people in the US every year. Hence, a rise in the target population base is expected to fuel the demand for early screening for effective treatment. Also, rising infections due to the Epstein-Barr virus, the Campylobacter jejuni bacteria, and others are expected to drive the growth of the market in focus during the forecast period.
Key Antinuclear Antibody Test Market Trend
Increasing prevalence of autoimmune diseases is one of the key antinuclear antibody test market trends that is expected to positively impact the industry in the forecast period. Patients with the autoimmune disorder Systemic Lupus Erythematosus (SLE) are almost always positive for ANA, however, a significant number of patients with other types of disorders may be positive for ANA also. Furthermore, with a predominant ratio of 7:1 in women versus men, SLE is thought to be due to an overexpression of the CD40LG and CXCR3 genes, which result from the lack of X Chromosome inactivation. A patient diagnosed with SLE experiences debilitating fatigue, fever, pain, and the characteristic butterfly rash seen on the face. In addition, the plaques can occur anywhere on the skin but are predominantly seen on the back, elbows, knees, and scalp. Moreover, with a prevalence of 11% in Caucasian and Scandinavian populations, psoriasis is generally prevalent among 2% of the global population. Such factors are expected to support the market growth in the coming years.
Key Antinuclear Antibody Test Market Challenge
One of the key challenges to the global antinuclear antibody test market growth is the stringent regulations for the approval of medical diagnostic. These regulations differ from country to country. For instance, In the US, the FDA's Center for Devices and Radiological Health (CDRH) regulates the development, testing, manufacturing, labeling, and marketing of medical diagnostic devices. ANA test kits are classified under Class II devices, with low-to-moderate risks. Hence, vendors must obtain premarket notification 510(k) before marketing such devices. In Europe, the European Medicines Agency (EMA) regulates all medical devices, including diagnostic devices, under the European Union (EU) legislation 2017/745, which came into force in May 2017. After the medical diagnostic device passes the conformity assessment, manufacturers obtain a CE mark certification for the device, which allows them to commercialize and market their products. Such a lengthy procedure may lead to delays in the commercial launch of products, which will hinder the growth of the global ANA test market.
This antinuclear antibody test market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Our report provides extensive information on the value chain analysis for the antinuclear antibody test market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
Technavio categorizes the global antinuclear antibody (ANA) test market as a part of the global life science tools and services market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the antinuclear antibody test market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the antinuclear antibody test market encompasses successful business strategies deployed by the key vendors. The antinuclear antibody test market is fragmented and the vendors are deploying growth strategies such as investment in R&D to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The antinuclear antibody test market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Antinuclear Antibody Test Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.93% |
Market growth 2022-2026 |
$ 447.71 million |
Market structure |
Fragmented |
YoY growth (%) |
7.24 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 38% |
Key consumer countries |
US, Germany, France, UK, and Japan |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Abbott Laboratories, Abcam Plc, Antibodies Inc., Bio Rad Laboratories Inc., BioVision Inc., Grifols SA, Immuno Concepts Ltd., Merck KGaA, Orgentec Diagnostika GmbH, PerkinElmer Inc., Quidel Corp., Seramun Diagnostica GmbH, Thermo Fisher Scientific Inc., Transasia Bio Medicals Ltd., Trinity Biotech Plc, Werfenlife SA, and ZEUS Scientific Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by End-user
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.